Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown. METHODS: We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode ultrasonography to assess the intima-media thickness of the walls of the carotid and femoral arteries. The primary outcome measure was the change in the mean carotid-artery intima-media thickness, which was defined as the average of the means of the far-wall intima-media thickness of the right and left common carotid arteries, carotid bulbs, and internal carotid arteries. RESULTS: The primary outcome, the mean (+/-SE) change in the carotid-artery intima-media thickness, was 0.0058+/-0.0037 mm in the simvastatin-only group and 0.0111+/-0.0038 mm in the simvastatin-plus-ezetimibe (combined-therapy) group (P=0.29). Secondary outcomes (consisting of other variables regarding the intima-media thickness of the carotid and femoral arteries) did not differ significantly between the two groups. At the end of the study, the mean (+/-SD) LDL cholesterol level was 192.7+/-60.3 mg per deciliter (4.98+/-1.56 mmol per liter) in the simvastatin group and 141.3+/-52.6 mg per deciliter (3.65+/-1.36 mmol per liter) in the combined-therapy group (a between-group difference of 16.5%, P<0.01). The differences between the two groups in reductions in levels of triglycerides and C-reactive protein were 6.6% and 25.7%, respectively, with greater reductions in the combined-therapy group (P<0.01 for both comparisons). Side-effect and safety profiles were similar in the two groups. CONCLUSIONS: In patients with familial hypercholesterolemia, combined therapy with ezetimibe and simvastatin did not result in a significant difference in changes in intima-media thickness, as compared with simvastatin alone, despite decreases in levels of LDL cholesterol and C-reactive protein. (ClinicalTrials.gov number, NCT00552097 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the earlier ENHANCE trial could not confirm that an addition of ezetimibe to statins significantly reduces intima-media thickness in patients with familial hypercholesterolemia, the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
In the citing paper
“the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationBots, M. L., Hoes, A. W., Koudstaal, P. J., Hofman, A., & Grobbee, D. E. (1997) · Circulation · doi:10.1161/01.cir.96.5.1432 · Cited by 2,345
Self-citationNiemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Self-citationBuchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Smilde, T., van Wissen, S., Awollersheim, H., Trip, M., Kastelein, J., & Stalenhoef, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04053-8 · Cited by 918
Self-citationTaylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Cited by
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
“emia, adding ezetimibe to simvastatin did not affect the progression of carotid IMT more than simvastatin alone.(179) In another”
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
“percholesterolemia despite a 17% lower level of LDL-C (622).”
BackgroundValidity and reliability of measurement instruments used in research
Kimberlin, C. L., & Winterstein, A. G. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070364 · Cited by 1,717
“Most recently, the Effect of Combination Ezetimibe and High-Dose Simvastatin vs Simvastatin Alone on the Atherosclerotic Process in Subjects with Heterozygous Familial Hypercholesterolemia (ENHANCE) trial found negative results for effects on intima–media thickness, even though the combination of ezetimibe and simvast…”
ResultGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
Goldstein, L. B., Bushnell, C. D., Adams, R. J., Appel, L. J., Braun, L. T., Chaturvedi, S., Creager, M. A., Culebras, A., Eckel, R. H., Hart, R. G., et al. (2011) · Stroke · doi:10.1161/str.0b013e3181fcb238 · Cited by 1,306
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Dyslipidemia in type 2 diabetes mellitus
Mooradian, A. D. (2009) · Nature Reviews Endocrinology · doi:10.1038/ncpendmet1066 · Cited by 1,042
“The results of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) tria”
ResultGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000624 · Cited by 907
Conflict of Interest in Medical Research, Education, and Practice
(2009) · National Academies Press eBooks · doi:10.17226/12598 · Cited by 807
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
Versmissen, J., Oosterveer, D. M., Yazdanpanah, M., Defesche, J. C., Basart, D. C. G., Liem, A. H., Heeringa, J., Witteman, J. C., Lansberg, P. J., Kastelein, J. J. P., et al. (2008) · BMJ · doi:10.1136/bmj.a2423 · Cited by 721
“In the recently published ENHANCE study, adding ezetimibe to the highest dose of simvastatin resulted in substantial further reductions of LDL cholesterol concentrations and high sensitivity C reactive protein levels but did not further reduce the carotid intima-media thickness.”
BackgroundSelf-citationCarotid Intima-Media Thickness and Plaque in Cardiovascular Risk Assessment
Naqvi, T. Z., & Lee, M.-S. (2014) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2013.11.014 · Cited by 649
“90 (11), indicating good test characteristics.”
Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness
Taylor, A. J., Villines, T. C., Stanek, E. J., Devine, P. J., Griffen, L., Miller, M., Weissman, N. J., & Turco, M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907569 · Cited by 644
Pleiotropic Effects of Statins - Basic Research and Clinical Perspectives -
Zhou, Q., & Liao, J. K. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0110 · Cited by 567
Jellinger, P. S., Smith, D. A., Mehta, A. E., Ganda, O., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
Tsujita, K., Sugiyama, S., Sumida, H., Shimomura, H., Yamashita, T., Yamanaga, K., Komura, N., Sakamoto, K., Oka, H., Nakao, K., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.065 · Cited by 459
“In the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) trial (11), the simvastatin/ ezetimibe combination failed to show a significant difference in intima-media thickness versus simvastatin alone.”
BackgroundFamilial hypercholesterolaemia
Defesche, J. C., Gidding, S. S., Harada-Shiba, M., Hegele, R. A., Santos, R. D., & Wierzbicki, A. S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.93 · Cited by 453
Reporting bias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010) · Trials · doi:10.1186/1745-6215-11-37 · Cited by 452
Willeit, P., Tschiderer, L., Allara, E., Reuber, K., Seekircher, L., Gao, L., Liao, X., Lonn, E., Gerstein, H. C., Yusuf, S., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046361 · Cited by 452
Self-citationRisk factors for venous and arterial thrombosis.
Previtali, E., Bucciarelli, P., Passamonti, S. M., & Martinelli, I. (2011) · PubMed · doi:10.2450/2010.0066-10 · Cited by 447
Brott, T. G., Halperin, J. L., Abbara, S., Bacharach, J. M., Barr, J. D., Bush, R. L., Cates, C. U., Creager, M. A., Fowler, S. B., Friday, G., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.006 · Cited by 447
Neil, A., Cooper, J., Betteridge, J., Capps, N., McDowell, I., Durrington, P., Seed, M., Humphries, S. E., & on behalf of the Simon Broome Familial Hyperlipidaemia Register Group (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn422 · Cited by 425
Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease
The Myocardial Infarction Genetics Consortium Investigators (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405386 · Cited by 419
Berger, M. L., Mamdani, M., Atkins, D., & Johnson, M. L. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00600.x · Cited by 409
“At the same time, recent studies of diabetes and lipid lowering drugs have raised concerns about relying on clinical trials that employ intermediate physiologic end points (e.g., glucose or lipid levels) rather than clinical outcomes (e.g., cardiovascular events) [34, 35 ].”
BackgroundHankey, G. J. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70255-2 · Cited by 384
A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices
Prasad, V., Vandross, A., Toomey, C., Cheung, M., Rho, J., Quinn, S., Chacko, S. J., Borkar, D., Gall, V., Selvaraj, S., et al. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.05.012 · Cited by 381
“Two studies suggested that although ezetimibe improves low-density lipoprotein values, it does not improve carotid artery intima media thickness.(37,38) Arthroscopic surgery of the knee for osteoarthritis was called into question by 2 studies 5 years apart,(39,40) whereas vertebroplasty for osteoporotic fracture was c…”
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Finn, A. V., Kolodgie, F. D., & Virmani, R. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.173609 · Cited by 350
Niemann-Pick C1-Like 1 (NPC1L1) Protein in Intestinal and Hepatic Cholesterol Transport
Jia, L., Betters, J. L., & Yu, L. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142233 · Cited by 356
“However, the outcome of the clinical trial ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) in 720 subjects with heterozygous familial hypercholesterolemia was disappointing, with no differences observed in carotid intimamedia thickness between the group on ezetimibe/simv…”
BackgroundUse of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
Ladenson, P. W., Kristensen, J. D., Ridgway, E. C., Olsson, A. G., Carlsson, B., Klein, I., Baxter, J. D., & Angelin, B. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905633 · Cited by 338
van den Oord, S. C. H., Sijbrands, E. J. G., ten Kate, G. L., van Klaveren, D., van Domburg, R. T., van der Steen, A. F. W., & Schinkel, A. F. L. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.01.025 · Cited by 315
Self-citationDyslipidaemia in nephrotic syndrome: mechanisms and treatment
Agrawal, S., Zaritsky, J. J., Fornoni, A., & Smoyer, W. E. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.155 · Cited by 325
Ezetimibe therapy: mechanism of action and clinical update
Toth, P., Phan, & Dayspring, T. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33664 · Cited by 288
“17,65,66 A recent meta-analysis was completed of 27 double-blind, placebo-controlled, or active comparative studies of over 21,000 subjects randomized to ezetimibe 10 mg daily plus statin or statin alone for a mean treatment of 9 weeks.”
InfluentialSahebkar, A. (2014) · Phytotherapy Research · doi:10.1002/ptr.5045 · Cited by 303
“…it has been suggested that combination therapy with statins and other types of hypolipidemic agents such as ezetimibe (Pearson et al., 2006; Kastelein et al., 2008), fenofibrate (Jones et al., 2009), and colesevelam (Bays et al., 2006) may yield greater reduction rates in circulating CRP…”
BackgroundAnti-inflammatory therapeutics for the treatment of atherosclerosis
Charo, I. F., & Taub, R. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3444 · Cited by 306
“Furthermore, the failure of a cholesterol-lowering agent to show a benefit in carotid intima medial thickness (IMT) in the ENHANCE tria”
BackgroundStatins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Zhou, Q., & Liao, J. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315684 · Cited by 294
Cannon, C. P., Giugliano, R. P., Blazing, M. A., Harrington, R. A., Peterson, J. L., Sisk, C. M., Strony, J., Musliner, T. A., McCabe, C. H., Veltri, E., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.07.023 · Cited by 299
Self-citationDyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management
Chehade, J. M., Gladysz, M., & Mooradian, A. D. (2013) · Drugs · doi:10.1007/s40265-013-0023-5 · Cited by 290
“In a pivotal trial of subjects with 36 % prevalence of diabetes, niacin added to statin therapy induced regression of CIMT and its effect was superior to addition of ezetimibe [61].”
BackgroundInfluentialLDL cholesterol: controversies and future therapeutic directions
Ridker, P. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61009-6 · Cited by 274
Morrone, D., Weintraub, W. S., Toth, P. P., Hanson, M. E., Lowe, R. S., Lin, J., Shah, A. K., & Tershakovec, A. M. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.02.016 · Cited by 263
“6% reduction with simvastatin 80 mg plus ezetimibe 10 mg) [49].”
BackgroundDiagnosis and treatment of familial hypercholesterolaemia
Hovingh, G. K., Davidson, M. H., Kastelein, J. J. P., & O'Connor, A. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht015 · Cited by 256
“13 However, the ENHANCE study showed that cIMT was not improved with the addition of ezetimibe to simvastatin despite substantial reductions in LDL-C.”
BackgroundInfluentialSelf-citationPatient-Important Outcomes in Registered Diabetes Trials
Gandhi, G. Y. (2008) · JAMA · doi:10.1001/jama.299.21.2543 · Cited by 252
Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes
Fleg, J. L., Mete, M., Howard, B. V., Umans, J. G., Roman, M. J., Ratner, R. E., Silverman, A., Galloway, J. M., Henderson, J. A., Weir, M. R., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.031 · Cited by 245
“No data are available on the influence of ezetimibe on therosclerosis except for findings from the ENHANCE Effect of Combination Ezetimibe and High-Dose Simvatatin Versus Simvastatin Alone on the Atherosclerotic rocess in Subjects With Heterozygous Familial Hyperchoesterolemia) trial (3).”
InfluentialPijlman, A. H., Huijgen, R., Verhagen, S. N., Imholz, B. P. M., Liem, A. H., Kastelein, J. J. P., Abbink, E. J., Stalenhoef, A. F. H., & Visseren, F. L. J. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.09.014 · Cited by 238
Self-citationDoes Carotid Intima-Media Thickness Regression Predict Reduction of Cardiovascular Events?
Costanzo, P., Perrone-Filardi, P., Vassallo, E., Paolillo, S., Cesarano, P., Brevetti, G., & Chiariello, M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.059 · Cited by 227
Pandor, A., Ara, R. M., Tumur, I., Wilkinson, A. J., Paisley, S., Duenas, A., Durrington, P. N., & Chilcott, J. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02062.x · Cited by 228
Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017
Harada-Shiba, M., Arai, H., Ishigaki, Y., Ishibashi, S., Okamura, T., Ogura, M., Dobashi, K., Nohara, A., Bujo, H., Miyauchi, K., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.cr003 · Cited by 221
Liu, P.-Y., Liu, Y.-W., Lin, L.-J., Chen, J.-H., & Liao, J. K. (2009) · Circulation · doi:10.1161/circulationaha.108.813311 · Cited by 226
Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis
Yu, X.-H., Zhang, D.-W., Zheng, X.-L., & Tang, C.-K. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.12.002 · Cited by 218
NPC1L1 and cholesterol transport
Betters, J. L., & Yu, L. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.03.030 · Cited by 215
“An earlier clinical trial ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) failed to show benefit of Vytorin (ezetimibe plus simvastatin) over simvastatin in improving the carotid artery intima-media thickness (IMT), though the combined therapy versus statin alone resulte…”
BackgroundHinojar, R., Foote, L., Arroyo Ucar, E., Jackson, T., Jabbour, A., Yu, C.-Y., McCrohon, J., Higgins, D. M., Carr-White, G., Mayr, M., et al. (2015) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2014.07.016 · Cited by 204
Douglas, P. S., DeCara, J. M., Devereux, R. B., Duckworth, S., Gardin, J. M., Jaber, W. A., Morehead, A. J., Oh, J. K., Picard, M. H., Solomon, S. D., et al. (2009) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2009.05.020 · Cited by 207
Familial hypercholesterolemia treatments: Guidelines and new therapies
Raal, F. J., Hovingh, G. K., & Catapano, A. L. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.859 · Cited by 194
Puntmann, V. O. (2009) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.073759 · Cited by 181
Management of Statin Intolerance in 2018: Still More Questions Than Answers
Toth, P. P., Patti, A. M., Giglio, R. V., Nikolic, D., Castellino, G., Rizzo, M., & Banach, M. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0259-7 · Cited by 186
Jones, M. L., Tomaro-Duchesneau, C., Martoni, C. J., & Prakash, S. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.758706 · Cited by 190
“However, reports have indicated that new drugs such as ezetimibe and torcetrapib, either have not shown an incremental reduction of secondary endpoints in atherosclerotic disease, such as carotid intimamedia thickness [27,28], or have had unanticipated adverse effects [29].”
BackgroundWriting Committee Members, Brott, T. G., Halperin, J. L., Abbara, S., Bacharach, J. M., Barr, J. D., Bush, R. L., Cates, C. U., Creager, M. A., Fowler, S. B., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182112cc2 · Cited by 174
Nambi, V., Chambless, L., He, M., Folsom, A. R., Mosley, T., Boerwinkle, E., & Ballantyne, C. M. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr192 · Cited by 175
Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers
Eichler, H.-G., Bloechl-Daum, B., Abadie, E., Barnett, D., König, F., & Pearson, S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3079 · Cited by 174
Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease
Pasterkamp, G., den Ruijter, H. M., & Libby, P. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.166 · Cited by 168
Guidelines for the Management of Familial Hypercholesterolemia
Harada-Shiba, M., Arai, H., Oikawa, S., Ohta, T., Okada, T., Okamura, T., Nohara, A., Bujo, H., Yokote, K., Wakatsuki, A., et al. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14621 · Cited by 176
Residual macrovascular risk in 2013: what have we learned?
(R3i), F. T. R. R. R. I., Fruchart, J.-C., Davignon, J., Hermans, M. P., Al-Rubeaan, K., Amarenco, P., Assmann, G., Barter, P., Betteridge, J., Bruckert, E., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-26 · Cited by 172
Carotid intima-media thickness as a biomarker of subclinical atherosclerosis
Bauer, M., Caviezel, S., Teynor, A., Erbel, R., Mahabadi, A. A., & Schmidt-Trucksäss, A. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13705 · Cited by 161
Molecular processes that handle — and mishandle — dietary lipids
Williams, K. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35206 · Cited by 160
Inflammation and the Development of Atherosclerosis
Mizuno, Y., Jacob, R. F., & Mason, R. P. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.7591 · Cited by 162
Writing Committee Members, Drozda, J., Messer, J. V., Spertus, J., Abramowitz, B., Alexander, K., Beam, C. T., Bonow, R. O., Burkiewicz, J. S., Crouch, M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31821d9ef2 · Cited by 161
MR Imaging of Carotid Plaque Composition During Lipid-Lowering Therapy
Zhao, X.-Q., Dong, L., Hatsukami, T., Phan, B. A., Chu, B., Moore, A., Lane, T., Neradilek, M. B., Polissar, N., Monick, D., et al. (2011) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2011.06.013 · Cited by 161
Surprises from genetic analyses of lipid risk factors for atherosclerosis
Musunuru, K., & Kathiresan, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306398 · Cited by 159
Reconsidering the Placebo Response from a Broad Anthropological Perspective
Thompson, J. J., Ritenbaugh, C., & Nichter, M. (2009) · Culture, Medicine, and Psychiatry · doi:10.1007/s11013-008-9122-2 · Cited by 159
Moriarty, P. M., Jacobson, T. A., Bruckert, E., Thompson, P. D., Guyton, J. R., Baccara-Dinet, M. T., & Gipe, D. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.09.007 · Cited by 154
Role of Lipotoxicity in Endothelial Dysfunction
Kim, J.-A., Montagnani, M., Chandrasekran, S., & Quon, M. J. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2012.06.012 · Cited by 144
Meuwese, M. C., de Groot, E., Duivenvoorden, R., Trip, M. D., Ose, L., Maritz, F. J., Basart, D. C. G., Kastelein, J. J. P., Habib, R., Davidson, M. H., et al. (2009) · JAMA · doi:10.1001/jama.301.11.1131 · Cited by 146
Self-citationHistorical perspectives on the impact of n-3 and n-6 nutrients on health
Lands, B. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.04.002 · Cited by 142
Metabolic Syndrome: Definition and Therapeutic Implications
Prasad, H., Ryan, D. A., Celzo, M. F., & Stapleton, D. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.01.2514 · Cited by 140
“when ezetimibe was added to simvastin compared with simvastin alone for 2 years.(89,90)”
Davidson, M. H., Maki, K. C., Dicklin, M. R., Feinstein, S. B., Witchger, M., Bell, M., McGuire, D. K., Provost, J.-C., Liker, H. R., & Aviram, M. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.05.037 · Cited by 140
Mata, N., Alonso, R., Badimón, L., Padró, T., Fuentes, F., Muñiz, O., Perez-Jiménez, F., López-Miranda, J., Díaz, J. L., Vidal, J. I., et al. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-94 · Cited by 136
Ito, M. K., McGowan, M. P., & Moriarty, P. M. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.04.001 · Cited by 151
Communicating Medical News — Pitfalls of Health Care Journalism
Dentzer, S. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0805753 · Cited by 127
de Lorgeril, M. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.184 · Cited by 130
“The publication of the JUPITER trial (in November 2008) was much anticipated since the announcement of the trial’s premature discontinuation in March 2008,(19,20) at a meeting of the American College of Cardiology, following the presentation of the disappointing results of the ENHANCE (Ezetimibe and Simvastatin in Hyp…”
Kotler, D. P. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318186519c · Cited by 129
Trends in lipid-modifying agent use in 83 countries
Blais, J. E., Wei, Y., Yap, K. K. W., Alwafi, H., Ma, T.-T., Brauer, R., Lau, W. C. Y., Man, K. K. C., Siu, C. W., Tan, K. C. B., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.016 · Cited by 131
Brott, T. G., Halperin, J. L., Abbara, S., Bacharach, J. M., Barr, J. D., Bush, R. L., Cates, C. U., Creager, M. A., Fowler, S. A., Friday, G. H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820d8c98 · Cited by 147
Huijgen, R., Kindt, I., Verhoeven, S. B. J., Sijbrands, E. J. G., Vissers, M. N., Kastelein, J. J. P., & Hutten, B. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009220 · Cited by 124
“20 based on the approximately 17% additional LDL-C lowering when added to statins.[14] The potency of a resin was estimated as 1.”
BackgroundSelf-citationChinese Guideline on the Primary Prevention of Cardiovascular Diseases
Chinese Society of Cardiology of Chinese Medical Association, C. D. P. A. R. C. O. C. A. O. R. M. (2021) · Cardiology Discovery · doi:10.1097/cd9.0000000000000025 · Cited by 132
Copayment Reductions Generate Greater Medication Adherence In Targeted Patients
Maciejewski, M. L., Farley, J. F., Parker, J., & Wansink, D. (2010) · Health Affairs · doi:10.1377/hlthaff.2010.0571 · Cited by 116
Surrogate Outcomes in Clinical Trials: A Cautionary Tale
Svensson, S. A., Menkes, D. B., & Lexchin, J. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.3037 · Cited by 133
Carotid Intima-Media Thickness: Knowledge and Application to Everyday Practice
Cobble, M. E., & Bale, B. F. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.01.2091 · Cited by 132
“This trial examined the role of combination simvastatin and ezetimibe versus simvastatin alone on lipids and CIMT measurements in patients with familial hypercholesterolemia.(43) The investigators found that although combination treatment signifi cantly reduced low-density lipoprotein cholesterol (LDL-C), triglyceride…”
BackgroundDemystifying the management of hypertriglyceridaemia
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.140 · Cited by 115
Park, J.-H., Park, Y. S., Kim, Y. J., Lee, I. S., Kim, J. H., Lee, J.-H., Choi, S. W., Jeong, J.-O., & Seong, I.-W. (2010) · Journal of Cardiovascular Ultrasound · doi:10.4250/jcu.2010.18.4.121 · Cited by 114
Disturbances in Cholesterol Homeostasis and Non-alcoholic Fatty Liver Diseases
Malhotra, P., Gill, R. K., Saksena, S., & Alrefai, W. A. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00467 · Cited by 109
“Studies showed that the inhibitor of cholesterol absorption ezetimibe reduces plasma cholesterol and decreases the risk of CVD when used alone or in combination with statins (67, 68).”
BackgroundInfluentialGuidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022
Harada‐Shiba, M., Arai, H., Ohmura, H., Okazaki, H., Sugiyama, D., Tada, H., Dobashi, K., Matsuki, K., Minamino, T., Yamashita, S., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.cr005 · Cited by 118
Robinson, J. G. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.2.139 · Cited by 123
Robinson, J. G., Williams, K. J., Gidding, S. S., Borén, J., Tabas, I. A., Fisher, E. A. A., Packard, C. J., Pencina, M. J., Fayad, Z. A., Mani, V., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009778 · Cited by 114
“medial thickness appears to be significantly modified only in statin na€ıve individuals, and that coronary artery calcium increases during statin therapy.(90,104,105) However, CT angiography, MRI, and PET/MRI or PET/CT have been shown to measure response to LDL-C lowering therapies such as statins and PCSK9 monoclonal…”
BackgroundEzetimibe for the prevention of cardiovascular disease and all-cause mortality events
Zhan, S., Tang, M., Liu, F., Xia, P., Shu, M., & Wu, X. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012502.pub2 · Cited by 109
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Management of patients with familial hypercholesterolaemia
Reiner, Ž. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.92 · Cited by 115
End Points for Clinical Trials in Acute Heart Failure Syndromes
Allen, L. A., Hernandez, A. F., O’Connor, C. M., & Felker, G. M. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.079 · Cited by 111
Dyslipidemia in women: etiology and management
Toth, P. P., & Phan, B. A. P. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s38133 · Cited by 124
Aortic valve calcification: basic science to clinical practice
Akat, K., Borggrefe, M., & Kaden, J. J. (2009) · Heart · doi:10.1136/hrt.2007.134783 · Cited by 103
Metadata
- Authors
- Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., & de Groot, E.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-04-03
- Volume
- 358
- Issue
- 14
- Pages
- 1431-1443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2120289695
- Semantic Scholar
- 0da4a48a4d402878a4b01330a3e43a185140f586
- Cited by
- 1,241
- References
- 34
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 16 · 2023: 20 · 2022: 14 · 2021: 24 · 2020: 27 · 2019: 35 · 2018: 30 · 2017: 38 · 2016: 50 · 2015: 77 · 2014: 91 · 2013: 85 · 2012: 111
- FWCI
- 210.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- simvastatin, ezetimibe, familial hypercholesterolemia, LDL cholesterol lowering, atherosclerosis progression, carotid intima-media thickness, femoral artery, cholesterol absorption inhibition, triglycerides, C-reactive protein, statin combination therapy, lipid-lowering therapy, atherosclerotic plaque regression
- MeSH terms
- Ezetimibe, Adult, Anticholesteremic Agents, Azetidines, Carotid Arteries, Cholesterol, Double-Blind Method, Drug Therapy, Combination, Female, Femoral Artery, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Ultrasonography, Treatment Outcome, Tunica Intima, Tunica Media, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.